B ACUTE LYMPHOBLASTIC LEUKEMIA

This study tests whether adding levocarnitine, a natural nutrient, to standard chemotherapy can prevent severe liver damage in teens and young adults (ages 15-39) with leukemia or lymphoma. Liver toxicity from the chemotherapy drug asparaginase often forces treatment delays, whic…

This large phase 3 trial studies whether different combinations and doses of chemotherapy drugs can better control high-risk B-acute lymphoblastic leukemia (B-ALL) in nearly 6,000 children and young adults. It includes a special group with Ph-like mutations who receive the target…

This large phase 3 study tests whether adding the drug blinatumomab to standard chemotherapy helps prevent cancer from returning in children and young adults with newly diagnosed B-cell leukemia or lymphoma, including those with Down syndrome. About 6,720 participants receive tre…

This early-phase study tests a treatment that uses a patient's own immune cells, modified to recognize and attack cancer cells, for adults with B-cell blood cancers that have returned or not responded to standard therapy. The treatment is given with chemotherapy and sometimes an …

This study compares a new treatment that combines a targeted drug (inotuzumab) with standard chemotherapy against chemotherapy alone for older adults with B-cell acute lymphoblastic leukemia or lymphoma. The targeted drug works like a smart bomb, attaching to cancer cells and del…

This study tests two drug combinations for adults aged 65 and older with acute lymphoblastic leukemia (ALL). One group gets blinatumomab plus standard chemotherapy; the other gets blinatumomab, dasatinib, and prednisone. The goal is to see if these combos help control the cancer …

This early-stage study tests a new cellular therapy for adults with high-risk acute lymphoblastic leukemia (ALL) that has come back or not responded to treatment. Researchers take a patient's own white blood cells, add a gene to help them recognize and attack cancer cells, and in…

This early-phase study tests a combination of drugs, including venetoclax, for adults with a specific type of leukemia (Ph+ ALL) that is either newly diagnosed or has returned. The goal is to find the safest dose and see how well the treatment works. About 20 participants will re…

This study looks at children and teens with a specific type of leukemia called Philadelphia chromosome-positive ALL. It tests whether a targeted drug called imatinib works as well with a milder chemotherapy regimen as it does with a stronger one, but with fewer side effects. The …

This early-stage trial tests whether a personalized cell therapy (CAR T-cells) can safely prevent relapse in older adults with B-cell acute lymphoblastic leukemia who are already in first remission. About 18 participants will receive their own immune cells, modified in a lab to t…

This study tests a drug called inotuzumab ozogamicin in 40 adults with B-cell acute lymphoblastic leukemia who still have tiny amounts of cancer cells after treatment. The drug works like a smart bomb, attaching to a protein on cancer cells and killing them. The goal is to see if…